Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

“The combination, which was generally well tolerated, provided durable benefit even in patients with adverse cytogenetics, as well as in both younger and older patients. It may also delay the need for transplant in some patients, although larger randomized trials are needed to confirm these findings.”

"We are seeing increasing interest from physicians to explore ways to optimize multiple myeloma treatment combinations using VELCADE as a foundation of myeloma therapy, across a broad spectrum of patients," said Nancy Simonian, M.D., Chief Medical Officer, Millennium.

Source:

Millennium: The Takeda Oncology Company

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs found to lower cancer risk in diabetes patients